Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease

Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease

Copyright © 2013 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 147(2013), 2 vom: 01. Mai, Seite 122-8
1. Verfasser: Kawai, Toshinao (VerfasserIn)
Weitere Verfasser: Watanabe, Nobuyuki, Yokoyama, Midori, Arai, Katsuhiro, Oana, Shinji, Harayama, Shizuko, Yasui, Kozo, Oh-Ishi, Tsutomu, Onodera, Masafumi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Journal Article Research Support, Non-U.S. Gov't Cytokines Immunosuppressive Agents Interleukin-1beta Lipopolysaccharides NF-kappa B Tumor Necrosis Factor-alpha Thalidomide mehr... 4Z8R6ORS6L Adenosine Triphosphate 8L70Q75FXE Caspase 1 EC 3.4.22.36
Beschreibung
Zusammenfassung:Copyright © 2013 Elsevier Inc. All rights reserved.
Chronic granulomatous disease (CGD) is a rare inherited disorder characterized by an inability to produce reactive oxygen species, resulting in recurrent life-threatening infections. Curiously, half of the patients with CGD suffer from aseptic bowel inflammation (CGD colitis) due to dysregulated inflammation induced by TNF-α and IL-1β. Thus, developing therapies that regulate excessive inflammatory responses without interrupting antimicrobial immunity would benefit CGD colitis patients. Here, we show that thalidomide suppressed TNF-α-induced NF-κB activation and ATP-induced IL-1β secretion, but did not interrupt the production of IL-1β, IL-6, IL-8, and TNF-α in response to lipopolysaccharide in CGD monocytes. We report on a CGD colitis patient that showed decreased bowel inflammation characterized by reduced serum levels of inflammatory cytokines without evidence of progression of fungal and bacterial infections present at initiation of thalidomide therapy. Our results suggest that thalidomide could be an efficacious therapeutic option for patients with CGD colitis suffering from serious infections
Beschreibung:Date Completed 20.06.2013
Date Revised 21.11.2013
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2013.03.004